2,290.00
-10.00
(-0.43%)
At close: January 17 at 3:45:00 PM GMT+9
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
978,646,000.00
936,210,000.00
881,923,000.00
750,123,000.00
730,544,000.00
Cost of Revenue
315,797,000.00
311,087,000.00
285,074,000.00
243,423,000.00
271,014,000.00
Gross Profit
662,849,000.00
625,123,000.00
596,849,000.00
506,700,000.00
459,530,000.00
Operating Expense
552,383,000.00
581,167,000.00
410,731,000.00
362,004,000.00
378,140,000.00
Operating Income
110,466,000.00
43,956,000.00
186,118,000.00
144,696,000.00
81,390,000.00
Net Non Operating Interest Income Expense
-3,651,000.00
-7,744,000.00
-4,315,000.00
-4,487,000.00
-5,175,000.00
Pretax Income
106,710,000.00
35,854,000.00
182,294,000.00
141,701,000.00
76,810,000.00
Tax Provision
18,206,000.00
8,881,000.00
44,304,000.00
31,074,000.00
11,140,000.00
Net Income Common Stockholders
75,248,000.00
242,566,000.00
143,432,000.00
115,742,000.00
12,918,000.00
Diluted NI Available to Com Stockholders
75,248,000.00
242,566,000.00
143,432,000.00
115,742,000.00
12,918,000.00
Basic EPS
68.34
199.91
113.22
90.22
10.05
Diluted EPS
67.79
199.44
113.08
90.17
10.04
Basic Average Shares
1,170,929.00
1,213,376.02
1,266,848.00
1,282,920.00
1,285,607.00
Diluted Average Shares
1,174,843.50
1,216,235.46
1,268,371.00
1,283,603.00
1,286,214.00
Total Operating Income as Reported
110,361,000.00
43,598,000.00
186,609,000.00
146,188,000.00
81,985,000.00
Total Expenses
868,180,000.00
892,254,000.00
695,805,000.00
605,427,000.00
649,154,000.00
Net Income from Continuing & Discontinued Operation
75,248,000.00
242,566,000.00
143,432,000.00
115,742,000.00
12,918,000.00
Normalized Income
88,504,000.00
26,610,000.00
137,809,000.00
110,399,000.00
65,599,000.00
Interest Income
3,268,000.00
2,562,000.00
3,860,000.00
1,351,000.00
1,193,000.00
Interest Expense
6,919,000.00
10,306,000.00
8,175,000.00
5,838,000.00
6,368,000.00
Net Interest Income
-3,651,000.00
-7,744,000.00
-4,315,000.00
-4,487,000.00
-5,175,000.00
EBIT
113,629,000.00
46,160,000.00
190,469,000.00
147,539,000.00
83,178,000.00
EBITDA
179,766,000.00
112,100,000.00
257,210,000.00
212,154,000.00
143,115,000.00
Reconciled Cost of Revenue
315,797,000.00
311,087,000.00
285,074,000.00
243,423,000.00
271,014,000.00
Reconciled Depreciation
66,137,000.00
65,940,000.00
66,741,000.00
64,615,000.00
59,937,000.00
Net Income from Continuing Operation Net Minority Interest
88,504,000.00
26,610,000.00
137,809,000.00
110,399,000.00
65,599,000.00
Normalized EBITDA
179,766,000.00
112,100,000.00
257,210,000.00
212,154,000.00
143,115,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
3/31/2021 - 1/4/2000
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
4543.T Terumo Corporation
2,915.50
-1.07%
ALC.SW Alcon Inc.
77.20
+0.99%
DIM.PA Sartorius Stedim Biotech S.A.
197.00
-0.73%
YPSN.SW Ypsomed Holding AG
342.00
-1.30%
SOON.SW Sonova Holding AG
302.60
-0.39%
BLFS BioLife Solutions, Inc.
26.14
-1.17%
IART Integra LifeSciences Holdings Corporation
24.10
+3.70%
ELMD Electromed, Inc.
34.00
+0.38%
TMCI Treace Medical Concepts, Inc.
8.71
+5.58%
CTKB Cytek Biosciences, Inc.
5.46
-0.55%